With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.
Continue reading "For Novartis, 2012 Is Set To Be A Bumpy Ride" »
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
Continue reading "U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy" »
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
Continue reading "Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe" »
There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.
Continue reading "Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain" »
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
Continue reading "The End of The Euro: What Might It Mean For Pharma?" »
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
Continue reading "The End of The Euro: What Might It Mean For Pharma?" »
In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.
Continue reading "French Pharma Industry Pays The Price For Country’s Financial Woes" »
The biggest changes in the European Commission's revised proposals on how pharmaceutical manufacturers can provide information to patients don't have to do with communications to patients at all - they address reporting safety concerns to regulators.
Continue reading "Lacking Mediator EC Tightens Pharmacovigilance Proposals " »
The Swedish government published on Sept. 22 a framework directive designed to revolutionize the pricing, reimbursement of and access to patent-protected pharmaceuticals.
Continue reading "Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs " »
Germany's pharmaceutical sector restructuring law (AMNOG) is living up to the government's expectations by putting the brakes on the country's drug expenditure.
Continue reading "Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma " »